Background: Fludarabine/busulfan-based conditioning regimens are widely used to perform allogeneic stem-cell transplantation (allo-SCT) in high-risk non-Hodgkin lymphoma (NHL) patients. The impact of the dose intensity of busulfan on outcomes has not been reported yet.
Background: Fludarabine/busulfan-based conditioning regimens are widely used to perform allogeneic stem-cell transplantation (allo-SCT) in high-risk non-Hodgkin lymphoma (NHL) patients. The impact of the dose intensity of busulfan on outcomes has not been reported yet.
Patients and methods:
This was a retrospective with the aim to compare the outcomes of NHL patients who received before allo-SCT a fludarabine/busulfan conditioning regimen, either of reduced intensity (FB2, 2 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n ¼ 277) or at a myeloablative reduced-toxicity dose (FB3/FB4, 3 or 4 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n ¼ 101).
Results: In univariate analysis, the 2-year overall survival (FB2 66.5% versus 60.3%, P ¼ 0.33), lymphoma-free survival (FB2 57.9% versus 49.8%, P ¼ 0.26), and non-relapse mortality (FB2 19% versus 21.1%, P ¼ 0.91) were similar between both groups. Cumulative incidence of grade III-IV acute graft versus host disease (GVHD) (FB2 11.2% versus 18%, P ¼ 0.08), extensive chronic GVHD (FB2: 17.3% versus 10.7%, P ¼ 0.18) and 2-year GVHD free-relapse free survival (FB2: 44.4% versus 42.8%, P ¼ 0.38) were also comparable. In multivariate analysis there was a trend for a worse outcome using FB3/FB4 regimens (overall survival: HR 1.47, 95% CI: 0.96-2.24, P ¼ 0.08; lymphoma-free survival: HR: 1.43, 95% CI: 0.99-2.06, P ¼ 0.05; relapse incidence: HR 1.54; 95% CI: 0.96-2.48, P ¼ 0.07). These results were confirmed using a propensity score-matching strategy.
Introduction
Non-Hodgkin lymphomas (NHL) include a very heterogeneous group of hematological malignancies, the prognosis of which is extremely variable from one entity to another. Most aggressive NHL cases can be cured with chemotherapy alone or combined with immunotherapy (for B-cell lymphoma) while prolonged disease control is generally obtained for indolent NHL patients with this treatment. Autologous stem-cell transplant (auto-SCT) is recommended for patients with insufficient response, refractory disease or early relapse after first-line therapy in case of chemosensitivity after salvage regimens [1] . The role of allogeneic stem-cell transplantation (allo-SCT) is more controversial [2] [3] [4] [5] [6] [7] , but this strategy is generally proposed for selected patients relapsing after auto-SCT [3, [6] [7] [8] [9] [10] [11] .
In 2010, allo-SCT for NHL represented 9% of all allo-SCT carried out in Europe and this proportion is increasing [12] . The optimal conditioning regimen in this setting, as well as the impact of reduced-intensity conditioning (RIC) is still unknown [6] . Fludarabine/busulfan-based conditioning regimens are however widely used for this purpose since they are less toxic than standard myeloablative procedures using total body irradiation/cyclophosphamide or busulfan/cyclosphosphamide [13, 14] , especially for these previously heavily treated patients. The busulfan dose intensity discriminates between the RIC such as the FB2 regimen (2 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) and the reduced-toxicity myeloablative conditioning called such as the FB3/FB4 (3 or 4 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/ day i.v.) [15] . The impact of a higher busulfan dose as part of the fludarabine/busulfan regimens may be favorable as it was recently described on retrospective studies in acute myeloid leukemia (AML) [16, 17] .
Currently there are no such data available in patients allografted for NHL. We hypothesized that the busulfan dose intensity may also have an impact on the outcome for these patients.
Materials and methods

Eligibility criteria and study design
This large retrospective study was conducted on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), including all adults (!18 years old) receiving allo-SCT for NHL (n ¼ 398) in France between January 2004 and December 2014. Conditioning included FB2 reduced intensity (n ¼ 277) or FB3/FB4 reduced-toxicity myeloablative (n ¼ 101), in combination or not with anti-thymoglobulin (ATG). FB3 and FB4 patients were pooled as they represent the two reduced toxicity myeloablative conditioning regimens and also because of the small number of patients in the FB4 subgroup (n ¼ 23). Inclusion of all types of NHL was allowed. Clinical data were obtained through ProMISe (Project Manager Internet Server), an internet-based system shared by all European transplantation centers. All patients provided informed consent for anonymously collecting their personal data in the ProMISe database before SCT.
Statistical analyses
The clinical outcomes studied were 2-year overall survival (OS), lymphoma-free survival (LFS), relapse incidence (RI) and non-relapse mortality (NRM). OS was defined as the time from day 0 of allo-SCT to death or last follow-up for survivors. LFS was defined as time from day 0 of allo-SCT to time without evidence of relapse or disease progression censored at the date of death or last follow-up. Relapse was defined as any event related to re-occurrence of the disease. NRM was defined as death from any cause without previous relapse or progression. Probabilities of OS and LFS were calculated using the log-rank test and Kaplan-Meier graphical representation. Cumulative incidence functions (CIF) [18] were used to estimate RI and NRM in a competing risks setting. In order to study acute and chronic graft versus host disease (GVHD), we considered death and relapse as competing events. Acute and chronic GVHD were diagnosed and graded according to standard criteria [19, 20] . The GVHD-free/relapse-free survival (GRFS), defined as alive with no previous grade III and IV aGvHD, no moderate or severe chronic GvHD and no relapse [21] , was also studied. Survival probabilities are presented as percentages and 95% confidence intervals (95% CI). Status at transplant [such as complete remission (CR), partial response (PR) and active disease (AD)] were established according to standard criteria [22] . AD was defined as stable disease (<50% reduction in the disease burden), progression (increase of >25% disease burden) or refractory disease [22] . Univariate analyses were carried out using the log-rank test for OS and LFS and the Gray test for CIF. Characteristics considered for univariate analysis are given in supplementary File, available at Annals of Oncology online. Multivariate analyses were carried out using the Cox proportional-hazard model. Factors differing between the two groups in terms of distribution and factors significantly associated with the outcome were included in the multivariate analysis.
To account for potential confounding factors between treatments that could influence outcome, the propensity score matching [2 FB2 (n ¼ 184) with each FB3/4 patients (n ¼ 98)] was also applied, using the nearest neighbor or exact matching [23] . Factors included in the propensity score model are given in supplementary File, available at Annals of Oncology online.
All tests were two-sided and P values <0.05 were considered as indicating a statistically significant association. Analyses were carried out using the R statistical software version 3.2.3 (available online at http://www.Rproject.org), and propensity score analysis was carried out using the 'MatchIt' [24] . Patients with missing values were excluded from propensity score analyses.
Results
Characteristics of the whole cohort
Overall, 378 patients were identified in the database, including 277 with FB2 (73%) and 101 with FB3/FB4 (27%). Types of NHL are described in supplementary File, available at Annals of Oncology online (Table 1) .
The median age was 57 years (range: 19-70) and most patients were in CR at the time of transplant (n ¼ 241, 63.8%, PR 28.6%, AD 7.7%). Almost all cases received a peripheral blood SCT (n ¼ 353, 98.4%) from a matched donor (sibling n ¼ 168, 44.4%, unrelated n ¼ 203, 53.7%, mis-matched n ¼ 7, 1.9%). Most patients received ATG as part of the conditioning regimen (FB2 83.8% versus FB3/4 84.2%, P ¼ 0.93) for GVHD prophylaxis. GVHD prophylaxis after transplant was then calcineurin inhibitor alone or combined with others drugs, depending mainly on the type of donors (related ¼ calcineurin inhibitor alone, unrelated: calcineurin inhibitor combined) as described by Mohty et al in 2015 [25] . (Table 1) . Sixty-one (16.1%) cases did not receive ATG as GVHD prophylaxis. FB2 or FB3/FB4 regimens were chosen according to physician discretion.
Conditioning regimens
Comparison of both groups
FB2 patients were older (median 57.3 versus 53.1 years, P ¼ 0.07), and had been more frequently autografted (69% versus 50.5%, P ¼ 0.001). FB3/FB4 patients had been allotransplanted earlier during the evolution of their disease (median time between diagnosis and allograft: 18.2 versus 33.8 months, P < 0.0001). The engraftment rate was similar between the 2 groups: FB2 group: 97.8%, FB3/4 group: 100% (P ¼ 0.13) (Table 1) . Unfortunately, no sufficient data are available regarding hepatic toxicity or chimerism in this study. However, the number of deaths due to veno-occlusive disease was comparable between the two groups (FB2 n ¼ 2; FB3/4 n ¼ 1).
Univariate analysis. 
Discussion
This retrospective study showed that higher busulfan dose as part of a fludarabine/busulfan conditioning regimen does not improve the outcome for NHL patients receiving allo-SCT. There was only a trend for worse outcomes with FB3/FB4 regimens, due to higher relapse rates and a significantly higher risk of severe grade III/IV acute GVHD, as shown on multivariate analysis. The latter is easily understandable as myeloablative conditioning may be associated with a greater risk of acute GVHD just because of increased mucosal and hepatic toxicities leading to a greater cytokine storm effect. The reason for the former (higher risk of relapse) is less clear. Busulfan is an alkylating agent with intersignificant variability in terms of pharmacokinetics. Monitoring plasma busulfan levels have been shown to be important to minimize the risk of toxicity and relapse after transplant [26] . Moreover, the only known route of clearance and detoxification of busulfan is by glutathione-S-transferases-mediated conjugation and the influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics has been largely reported [27, 28] . It is not known if any of these issues played a part in the observed higher risk of relapse in the FB3/FB4 group, as data on dose adjustments or GTS polymorphism studies were not available in this cohort. Finally, resistance to busulfan can be discussed: this phenomenon is multifactorial [29] , including various mechanisms such as loss of DNA-mismatch repair activity by tumor cells [30] . The current analysis has several inherent limitations. First, as it may occur in any multicenter registry study, the two groups were unevenly balanced in terms of patient characteristics. The retrospective design did not allow the identification of reason for choosing FB3/4-or FB2, which may vary according to pretransplant characteristics. It may be hypothesized that for the FB3/FB4 sub-group, which included younger and less frequently previously autografted patients, the physician choice aimed at intensifying the conditioning regimen, with the hope to obtain a better outcome. A score matching was used in order to address these limitations, assessing the probability of treatmentassignment conditional to observed pre-transplant characteristics. This confirmed that FB3/FB4 regimens were not superior to FB2, with no differences in relapse or severe acute GVHD incidences between the two groups. In fact, our results confirm two previous studies, one in the myeloid setting [31] and another including a heterogeneous cohort of patients with both lymphoid and myeloid tumors [32] . However, if comparison between FB1 and FB2 regimens have shown equivalence for myeloid malignancies [33] , a higher busulfan dose may be of beneficial for some patients. Indeed, for younger patients with AML in first CR, one study has shown that the FB4 regimen was associated with a lower risk of relapse than that observed with the FB2 regimen [16] . A second study, analyzing to AML patients in second CR, showed that the FB4 regimen improves LFS and OS compared with the FB2 regimen [16] . Interestingly, none of the above mentioned studies using FB4 [16, 19, 31] showed an increased risk of severe GVHD with this regimen, contrary to what was observed here.
With a 60%-66% 2-year OS and a 50%-58% 2-year LFS, the results of this cohort are overall similar to what has been published for NHL patients after allo-SCT. Analyses according to lymphoma subtypes also confirmed the better survival rates observed in patients with low grade NHL [10, 34] . The outcome of T-cell lymphoma patients was particularly interesting showing a 2-year OS of 71.8% and low incidences of NRM (11.6%) or severe grade III and IV acute GVHD (8.5%). Most of these patients (67.7%) had not been previously autografted while almost half (48.1%) had received allo-SCT as first line therapy. The benefit of performing allo-SCT early for high risk T-cell lymphoma has been previously demonstrated and should probably be taken into account [35, 36] . NRM was high for MCL patients as reported [9, 37] and may be linked to the high rate of previously autografted patients in this group. Survival for aggressive NHL was lower compared with other lymphoma subtypes (2-years LFS: 43.7%, 2-years OS: 51.4%), also as described before [12, 38] , indicating that strategies to improve the results of allo-SCT are highly needed. For this purpose, new conditioning regimens may be developed. Use of treosulfan, a second generation alkylating agent [39] , or radioimmunotherapy [40] as part of the conditioning regimen have shown encouraging results. Post-transplant strategies using pre-emptive donor lymphocyte infusions and/or new drugs, such as Bruton tyrosine kinase inhibitors for B-cell lymphoma [41] may help also to reach this objective [9] . The possibility to consider haplo-identical allo-SCT with post-transplant cyclophosphamide could also allow to propose allo-SCT rapidly in cases with no matched donor and NHL at high risk of early relapse [42] .
In conclusion, this large retrospective study showed that reduced toxicity myeloablative fludarabine/busulfan regimens did not improve the outcomes of adults allografted for NHL. FB2 may thus be considered as one of the standard of care regimen in this setting. To validate these results, prospective studies are needed, such as the one currently ongoing in France for myeloid diseases (NCT01985061).
